Biologically, the results reinforce the dual role of TGF-β signaling in colorectal cancer: functioning as a tumor suppressor in early stages, but shifting toward pro-metastatic, immune-evasive, and chemoresistant roles when disrupted through alterations in key regulators such as SMAD4 and BMPR1A. This evidence concerns the gene TGFB1 and neoplasm.